Current Opinion in Lipidology,
Journal Year:
2024,
Volume and Issue:
35(6), P. 303 - 309
Published: Oct. 17, 2024
Purpose
of
review
To
the
evidence
and
describe
biological
plausibility
for
benefits
inhibiting
cholesteryl
ester
transfer
protein
(CETP)
on
multiple
organ
systems
through
modification
lipoprotein
metabolism.
Recent
findings
Results
from
observational
studies,
Mendelian
randomization
analyses,
randomized
clinical
trials
support
potential
CETP
inhibition
to
reduce
atherosclerotic
cardiovascular
disease
(ASCVD)
risk
a
reduction
apolipoprotein
B-containing
lipoproteins.
In
contrast,
raising
high-density
(HDL)
particles,
as
previously
hypothesized,
did
not
contribute
ASCVD
reduction.
There
is
also
an
expanding
body
supporting
safeguarding
against
other
conditions
associated
with
aging,
particularly
new-onset
type
2
diabetes
mellitus
dementia,
well
age-related
macular
degeneration,
septicemia,
possibly
chronic
kidney
disease.
The
latter
are
likely
mediated
improved
functionality
HDL
particle,
including
its
role
cholesterol
efflux
antioxidative,
anti-inflammatory,
antimicrobial
activities.
Summary
At
present,
there
robust
reducing
activity
reduction,
exists
promotion
longevity
by
risks
several
conditions.
An
ongoing
large
trial
program
latest
potent
inhibitor,
obicetrapib,
expected
provide
further
insight
into
therapeutic
target
these
various
Clínica e Investigación en Arteriosclerosis,
Journal Year:
2024,
Volume and Issue:
36, P. S15 - S23
Published: Dec. 1, 2024
Despite
the
various
therapeutic
tools
available,
many
patients
do
not
achieve
goals,
and
cardiovascular
diseases
remain
a
significant
cause
of
death
in
our
setting.
Furthermore,
even
who
manage
to
reduce
their
LDL-C
levels
recommended
targets,
events
continue
occur.
The
challenge
persistent
risk
have
led
active
research
into
new
drugs
targeting
novel
pathways
field
lipoprotein
metabolism
disorders.
approach
involves
pharmacological
mechanisms,
ranging
from
small
molecules
monoclonal
antibodies
RNA
interference,
with
inclisiran
being
first
drug
approved
for
clinical
use
domain.
In
this
review,
we
aim
provide
comprehensive
overview
targets
mechanisms
under
development,
as
well
potential
impact.
Clinical Research in Cardiology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 11, 2024
Elevated
levels
of
lipoprotein(a)
(Lp[a])
have
been
recognized
as
substantial
risk
factors
for
cardiovascular
disease
and
aortic
stenosis
(AS).
However,
the
specific
role
Lp(a)
in
promoting
valve
calcification
(AVC)
influencing
mortality
elderly,
multimorbid
patients
undergoing
transcatheter
replacement
(TAVR)
remains
unclear
warrants
further
investigation.
Expert Opinion on Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 9
Published: Dec. 22, 2024
Lipid-lowering
therapies
are
well
established
for
the
treatment
of
cardiovascular
disease
(CVD).
Historically
monotherapy
studies
have
been
performed,
but
introduction
statins
has
led
to
these
drugs
being
recognized
as
baseline
and
investigation
combination
therapy
both
older
newer
medications
with
them.
Current Opinion in Lipidology,
Journal Year:
2024,
Volume and Issue:
35(6), P. 303 - 309
Published: Oct. 17, 2024
Purpose
of
review
To
the
evidence
and
describe
biological
plausibility
for
benefits
inhibiting
cholesteryl
ester
transfer
protein
(CETP)
on
multiple
organ
systems
through
modification
lipoprotein
metabolism.
Recent
findings
Results
from
observational
studies,
Mendelian
randomization
analyses,
randomized
clinical
trials
support
potential
CETP
inhibition
to
reduce
atherosclerotic
cardiovascular
disease
(ASCVD)
risk
a
reduction
apolipoprotein
B-containing
lipoproteins.
In
contrast,
raising
high-density
(HDL)
particles,
as
previously
hypothesized,
did
not
contribute
ASCVD
reduction.
There
is
also
an
expanding
body
supporting
safeguarding
against
other
conditions
associated
with
aging,
particularly
new-onset
type
2
diabetes
mellitus
dementia,
well
age-related
macular
degeneration,
septicemia,
possibly
chronic
kidney
disease.
The
latter
are
likely
mediated
improved
functionality
HDL
particle,
including
its
role
cholesterol
efflux
antioxidative,
anti-inflammatory,
antimicrobial
activities.
Summary
At
present,
there
robust
reducing
activity
reduction,
exists
promotion
longevity
by
risks
several
conditions.
An
ongoing
large
trial
program
latest
potent
inhibitor,
obicetrapib,
expected
provide
further
insight
into
therapeutic
target
these
various
